ABOUT THIS BLOG

In November 2022 a phase 3 clinical trial was published in the highly regarded scientific New England Journal of Medicine describing how the monoclonal antibody Lecanemab slowed cognitive decline in patients with mild Alzheimer’s disease. Strikingly, over an 18-month treatment period, patients did better on the Clinical Dementia Rating Scale – sum of boxes (CDR-SB), and standardized Activities of Daily Living (ADL) instruments. In addition, biomarkers of disease were modified. The study made headlines throughout the world, and may represent a paradigm shift in how we treat Alzheimer’s.

For those of who you read the above paragraph with ease, this blog may not be for you, other than perhaps staying updated on the latest research that I would consider the most important. However, for those of you who read “Phase 3,” “monoclonal antibody,” “leceanemab”, “CDR-SB”, “ADL”, and “biomarkers,” and wondered what the heck this means and how it relates to the “real world,” this blog is for you. And if in addition to this you had not even heard of Lecanemab until now, even better. One of the things I enjoy as a dementia expert and neuroscientist is to explain complex science in a manner that makes sense to those who do not live and breathe science. I hope this blog will be an educational experience, and serve to keep you updated on the most important findings as we search for a cure for dementia. Please share with your friends and family!